CN111683659A - 一种氨基吡喃衍生物的组合物 - Google Patents

一种氨基吡喃衍生物的组合物 Download PDF

Info

Publication number
CN111683659A
CN111683659A CN201980012017.XA CN201980012017A CN111683659A CN 111683659 A CN111683659 A CN 111683659A CN 201980012017 A CN201980012017 A CN 201980012017A CN 111683659 A CN111683659 A CN 111683659A
Authority
CN
China
Prior art keywords
weight
compound
pharmaceutical formulation
formula
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012017.XA
Other languages
English (en)
Other versions
CN111683659B (zh
Inventor
莫毅
李洪湖
万星
叶飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN202310894572.8A priority Critical patent/CN116919952A/zh
Publication of CN111683659A publication Critical patent/CN111683659A/zh
Application granted granted Critical
Publication of CN111683659B publication Critical patent/CN111683659B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种通式(A)化合物或者药学上可接受的盐或前药的组合物及其制备方法。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN201980012017.XA 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物 Active CN111683659B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310894572.8A CN116919952A (zh) 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810108653 2018-02-06
CN201810108653X 2018-02-06
PCT/CN2019/073912 WO2019154218A1 (zh) 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310894572.8A Division CN116919952A (zh) 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物

Publications (2)

Publication Number Publication Date
CN111683659A true CN111683659A (zh) 2020-09-18
CN111683659B CN111683659B (zh) 2023-08-29

Family

ID=67548192

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310894572.8A Pending CN116919952A (zh) 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物
CN201980012017.XA Active CN111683659B (zh) 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310894572.8A Pending CN116919952A (zh) 2018-02-06 2019-01-30 一种氨基吡喃衍生物的组合物

Country Status (6)

Country Link
US (1) US11974985B2 (zh)
EP (1) EP3750539A4 (zh)
JP (1) JP7150862B2 (zh)
CN (2) CN116919952A (zh)
TW (1) TWI730289B (zh)
WO (1) WO2019154218A1 (zh)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
CN101410400A (zh) * 2006-03-28 2009-04-15 默克公司 作为用于糖尿病治疗或者预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
WO2011028455A1 (en) * 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN102272136A (zh) * 2008-11-13 2011-12-07 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
WO2015031228A1 (en) * 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
WO2015192714A1 (zh) * 2014-06-16 2015-12-23 四川海思科制药有限公司 吡咯并咪唑环衍生物及其在医药上的应用
WO2017032705A1 (en) * 2015-08-25 2017-03-02 Sandoz Ag Crystalline form of omarigliptin
CN106540265A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 一种奥格列汀药物组合物及其制备方法
CN106632349A (zh) * 2015-10-29 2017-05-10 四川海思科制药有限公司 吡喃衍生物的盐或其盐的水合物及其制备与应用
CN106928228A (zh) * 2015-12-29 2017-07-07 杭州普晒医药科技有限公司 奥格列汀盐及其晶型、它们的制备方法和药物组合物
WO2017202365A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物制备方法
WO2017202357A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物的制备方法
EP3335702A1 (en) * 2016-12-16 2018-06-20 Hexal AG Pharmaceutical compositions comprising omarigliptin
EP3335703A1 (en) * 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
CN109796455A (zh) * 2017-11-17 2019-05-24 四川海思科制药有限公司 一种氨基吡喃衍生物的盐、其晶形及其制备方法和用途
CN111253403A (zh) * 2018-12-03 2020-06-09 四川海思科制药有限公司 氨基吡喃氘代衍生物及其组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6535034B2 (ja) 2014-06-17 2019-06-26 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド アミノピラン環誘導体及びその組成物と用途
EP3181565A1 (en) * 2015-12-18 2017-06-21 Sandoz Ag Crystalline omarigliptin salts
CN106916157A (zh) * 2015-12-25 2017-07-04 四川海思科制药有限公司 取代的氨基吡喃衍生物的晶型

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410400A (zh) * 2006-03-28 2009-04-15 默克公司 作为用于糖尿病治疗或者预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
CN102272136A (zh) * 2008-11-13 2011-12-07 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
WO2011028455A1 (en) * 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2015031228A1 (en) * 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
WO2015192714A1 (zh) * 2014-06-16 2015-12-23 四川海思科制药有限公司 吡咯并咪唑环衍生物及其在医药上的应用
WO2017032705A1 (en) * 2015-08-25 2017-03-02 Sandoz Ag Crystalline form of omarigliptin
CN106540265A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 一种奥格列汀药物组合物及其制备方法
CN106632349A (zh) * 2015-10-29 2017-05-10 四川海思科制药有限公司 吡喃衍生物的盐或其盐的水合物及其制备与应用
CN106928228A (zh) * 2015-12-29 2017-07-07 杭州普晒医药科技有限公司 奥格列汀盐及其晶型、它们的制备方法和药物组合物
WO2017202365A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物制备方法
WO2017202357A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物的制备方法
EP3335702A1 (en) * 2016-12-16 2018-06-20 Hexal AG Pharmaceutical compositions comprising omarigliptin
EP3335703A1 (en) * 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
CN109796455A (zh) * 2017-11-17 2019-05-24 四川海思科制药有限公司 一种氨基吡喃衍生物的盐、其晶形及其制备方法和用途
CN111253403A (zh) * 2018-12-03 2020-06-09 四川海思科制药有限公司 氨基吡喃氘代衍生物及其组合物和应用

Also Published As

Publication number Publication date
WO2019154218A1 (zh) 2019-08-15
US11974985B2 (en) 2024-05-07
JP7150862B2 (ja) 2022-10-11
CN116919952A (zh) 2023-10-24
EP3750539A4 (en) 2021-12-15
JP2021512900A (ja) 2021-05-20
CN111683659B (zh) 2023-08-29
TWI730289B (zh) 2021-06-11
US20210059987A1 (en) 2021-03-04
EP3750539A1 (en) 2020-12-16
TW201934121A (zh) 2019-09-01

Similar Documents

Publication Publication Date Title
US6936274B2 (en) Storage stable thyroxine active drug formulations and methods for their production
EP1701698B1 (en) Directly compressible pharmaceutical composition for the oral admimistration of cci-779
HUE031227T2 (en) Dry granulation process for preparing metformin tablet compositions and compositions thereof
US7052717B2 (en) Storage stable thyroxine active drug formulations and methods for their production
KR101272470B1 (ko) 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2867199B1 (en) Stable compositions of fesoterodine
US7955620B2 (en) Stable oral composition
WO2021101482A1 (en) A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent
US11878078B2 (en) Instant release pharmaceutical preparation of anticoagulant and preparation method therefor
US20100003319A1 (en) Raloxifene immediate release tablets
WO2019244171A1 (en) Stable oral pharmaceutical composition of amorphous empagliflozin and process for preparing thereof
CN111683659B (zh) 一种氨基吡喃衍生物的组合物
US9271951B2 (en) Levothyroxine formulation with acacia
US20230064429A1 (en) IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
EP1560568B1 (en) Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate
WO2016135740A1 (en) Process for preparing stable oral compositions of everolimus
WO2022119540A2 (en) A process for formulations of dapagliflozin and metformin hydrochloride
JP2024090218A (ja) 崩壊遅延を改善したゾニサミド含有口腔内速崩壊錠
WO2014098886A1 (en) Levothyroxine formulation with carrageenan
WO2014098887A1 (en) Levothyroxine formulation with acacia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029191

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant